Phase I/II – First Administration

454 trials 191 recruiting

Filter these 454 trials by condition, country, sponsor and more.

Open in Search →

A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients wit… Ended

2024-514933-39-00 Patients with Advanced Tumors and Tenosynovial Giant Ce 2020-05-26
First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended

2024-515560-30-00 Advanced-stage, relapsed/refractory cancer 2020-03-05
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1… Ended

2024-515504-39-00 Patients with hematological malignancies (Cf. inclusion 2020-02-09
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended

2023-509550-55-00 Multiple Myeloma 2020-01-21
GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended

2023-508526-10-00 Malignant solid tumors: Patients with relapsed or refra 2019-10-01
PIGMENT – PDE6A gene therapy for retinitis pigmentosa Ended

2024-517924-20-00 PDE6A-linked Retinitis Pigmentosa 2019-09-24
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Ended

2023-509059-15-00 Malignant solid tumors: endometrial carcinoma (EC), uro 2019-04-30
A study to test IMGN632 in adults with CD123-positive Acute Myeloid Leukemia and other CD123 positive Hematologic cancers. Ended

2024-514195-40-00 Acute Myeloid Leukemia and other blood cancers 2019-02-28
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Lymphoma of B-cell origin 2018-05-16
Gene therapy study with autologous hematopoietic stem cells for patients affected by MPS-IH Ended

2024-514870-29-00 Mucopolysaccharidosis type I Hurler 2018-05-14
Talquetamab (GPRC5D and CD3 antibody) in Relapsed or Refractory Multiple Myeloma Ended

2023-504581-29-00 Multiple myeloma 2018-04-26
A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patient… Ended

2023-505222-34-00 Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma 2018-04-23
An Open label Study of Teclistamab in Subjects with Relapsed and Refractory Multiple Myeloma Ended

2023-503438-40-00 Relapsed/Refractory Multiple Myeloma 2017-10-05
A Phase 1/2 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumors. Ended

2023-507702-13-00 Male or female patients age 12 years or older with a lo 2017-09-22
A Study to Assess Safety, Effectiveness, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Patients with Paroxys… Ended

2023-506287-14-00 Paroxysmal nocturnal hemoglobinuria (PNH) 2017-04-21
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent … Ended

2023-505625-14-00 Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r 2017-01-31
A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723… Ended

2023-506144-16-00 Advanced Stage Solid Tumors 2016-12-06
A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended

2024-515846-18-00 Newly diagnosed Diffuse Large B Cell Lymphoma 2016-09-19
A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms Halted

2025-520786-44-00 Myelodysplastic syndromes 2025-10-21
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory A… Halted

2024-516641-39-00 Acute Myeloid Leukemia 2024-12-02
Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, rela… Halted

2024-519808-27-00 B-cell acute lymphoblastic leukemia. with resistance, r 2023-12-19
To investigate PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated re-lapsed/refractory AML or MDS/AML pa… Halted

2024-514051-15-00 Adult patients with relapsed or refractory IDH1-mutated 2023-07-10
A Phase I/II study of DYP688 treatment alone in patients with eye cancer and other types of cancers of the skin and mucosal membranes in the… Halted

2023-509451-14-00 Metastatic uveal melanoma 2022-11-01
A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug… Halted

2024-514588-24-00 Acute Myeloid Leukaemia (AML) 2021-09-27